These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 22726547)

  • 41. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.
    Pennisi A; Li X; Ling W; Khan S; Zangari M; Yaccoby S
    Am J Hematol; 2009 Jan; 84(1):6-14. PubMed ID: 18980173
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lrp4 in osteoblasts suppresses bone formation and promotes osteoclastogenesis and bone resorption.
    Xiong L; Jung JU; Wu H; Xia WF; Pan JX; Shen C; Mei L; Xiong WC
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3487-92. PubMed ID: 25733894
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Response to bortezomib and activation of osteoblasts in multiple myeloma.
    Zangari M; Yaccoby S; Cavallo F; Esseltine D; Tricot G
    Clin Lymphoma Myeloma; 2006 Sep; 7(2):109-14. PubMed ID: 17026821
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.
    Besse A; Besse L; Kraus M; Mendez-Lopez M; Bader J; Xin BT; de Bruin G; Maurits E; Overkleeft HS; Driessen C
    Cell Chem Biol; 2019 Mar; 26(3):340-351.e3. PubMed ID: 30612952
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
    Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
    Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interleukin-20 differentially regulates bone mesenchymal stem cell activities in RANKL-induced osteoclastogenesis through the OPG/RANKL/RANK axis and the NF-κB, MAPK and AKT signalling pathways.
    Meng B; Wu D; Cheng Y; Huang P; Liu Y; Gan L; Liu C; Cao Y
    Scand J Immunol; 2020 May; 91(5):e12874. PubMed ID: 32090353
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Osteoblastogenesis and tumor growth in myeloma.
    Yaccoby S
    Leuk Lymphoma; 2010 Feb; 51(2):213-20. PubMed ID: 20038269
    [TBL] [Abstract][Full Text] [Related]  

  • 48. GSK-3β inhibition suppresses instability-induced osteolysis by a dual action on osteoblast and osteoclast differentiation.
    Amirhosseini M; Madsen RV; Escott KJ; Bostrom MP; Ross FP; Fahlgren A
    J Cell Physiol; 2018 Mar; 233(3):2398-2408. PubMed ID: 28731198
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation.
    Boissy P; Andersen TL; Abdallah BM; Kassem M; Plesner T; Delaissé JM
    Cancer Res; 2005 Nov; 65(21):9943-52. PubMed ID: 16267019
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Osteoclast differentiation by RANKL and OPG signaling pathways.
    Udagawa N; Koide M; Nakamura M; Nakamichi Y; Yamashita T; Uehara S; Kobayashi Y; Furuya Y; Yasuda H; Fukuda C; Tsuda E
    J Bone Miner Metab; 2021 Jan; 39(1):19-26. PubMed ID: 33079279
    [TBL] [Abstract][Full Text] [Related]  

  • 51. IL-3 Differentially Regulates Membrane and Soluble RANKL in Osteoblasts through Metalloproteases and the JAK2/STAT5 Pathway and Improves the RANKL/OPG Ratio in Adult Mice.
    Singh K; Piprode V; Mhaske ST; Barhanpurkar-Naik A; Wani MR
    J Immunol; 2018 Jan; 200(2):595-606. PubMed ID: 29203513
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Embelin suppresses osteoclastogenesis induced by receptor activator of NF-κB ligand and tumor cells in vitro through inhibition of the NF-κB cell signaling pathway.
    Reuter S; Prasad S; Phromnoi K; Kannappan R; Yadav VR; Aggarwal BB
    Mol Cancer Res; 2010 Oct; 8(10):1425-36. PubMed ID: 20826545
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prostaglandin E(2) is a main mediator in receptor activator of nuclear factor-kappaB ligand-dependent osteoclastogenesis induced by Porphyromonas gingivalis, Treponema denticola, and Treponema socranskii.
    Choi BK; Moon SY; Cha JH; Kim KW; Yoo YJ
    J Periodontol; 2005 May; 76(5):813-20. PubMed ID: 15898943
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of OPG/TRAIL complex in multiple myeloma: the OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease.
    Brunetti G; Colucci S; Rizzi R; Mori G; Colaianni G; Oranger A; Zallone A; Liso V; Grano M
    Ann N Y Acad Sci; 2006 Apr; 1068():334-40. PubMed ID: 16831934
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.
    Udagawa N; Takahashi N; Jimi E; Matsuzaki K; Tsurukai T; Itoh K; Nakagawa N; Yasuda H; Goto M; Tsuda E; Higashio K; Gillespie MT; Martin TJ; Suda T
    Bone; 1999 Nov; 25(5):517-23. PubMed ID: 10574571
    [TBL] [Abstract][Full Text] [Related]  

  • 56. RANK ligand and osteoprotegerin in myeloma bone disease.
    Sezer O; Heider U; Zavrski I; Kühne CA; Hofbauer LC
    Blood; 2003 Mar; 101(6):2094-8. PubMed ID: 12424190
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway.
    Palmqvist P; Lundberg P; Persson E; Johansson A; Lundgren I; Lie A; Conaway HH; Lerner UH
    J Biol Chem; 2006 Feb; 281(5):2414-29. PubMed ID: 16251181
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Natural Agents as Novel Potential Source of Proteasome Inhibitors with Anti-Tumor Activity: Focus on Multiple Myeloma.
    Ambrosio FA; Costa G; Gallo Cantafio ME; Torcasio R; Trapasso F; Alcaro S; Viglietto G; Amodio N
    Molecules; 2023 Feb; 28(3):. PubMed ID: 36771100
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation.
    Suda K; Udagawa N; Sato N; Takami M; Itoh K; Woo JT; Takahashi N; Nagai K
    J Immunol; 2004 Feb; 172(4):2504-10. PubMed ID: 14764723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.